Evidence map›Paper›PMID 32243311›Full record

SynthesisJournal of lower genital tract disease2020

Reporting and Assessing the Quality of Diagnostic Accuracy Studies for Cervical Cancer Screening and Management.

Megan A Clarke, Teresa M Darragh, Erin Nelson, Elizabeth R Unger, Rosemary Zuna, Miriam Cremer, Colleen K Stockdale, Mark H Einstein, Nicolas Wentzensen

Abstract readSystematic Review
In one paragraph

Synthesis in Journal of lower genital tract disease, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Guideline
  2. Guideline
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Megan A ClarkeDivision of Cancer Epidemiology & Genetics, National Cancer Institute/NIH, Bethesda, MD.
Teresa M DarraghDepartment of Pathology, University of California San Francisco, San Francisco, CA.
Erin NelsonDepartment of Obstetrics and Gynecology, University of Texas San Antonio, San Antonio, TX.
Elizabeth R UngerNational Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA.
Rosemary ZunaDepartment of Pathology, College of Medicine, University of Oklahoma, Oklahoma City, OK.
Miriam CremerWomen's Health, Cleveland Clinic, Cleveland, OH.
Colleen K StockdaleDepartment of Obstetrics and Gynecology, Carver College of Medicine, University of Iowa, Iowa City, IA.
Mark H EinsteinDepartment of Obstetrics, Gynecology & Women's Health, Rutgers New Jersey Medical School, Newark, NJ.
Nicolas WentzensenDivision of Cancer Epidemiology & Genetics, National Cancer Institute/NIH, Bethesda, MD.

Funding

Cervical Cancer MoonshotZIACP010230 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI SCHIFFMAN, MARK · 2018 to 2025
$33.8M
Human papillomavirus (HPV) infection and cervical and anal cancersZIACP010124 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI WENTZENSEN, NICOLAS · 2009 to 2025
$17.3M
Intramural NIH HHS ZIA CP010124
6 · The paper itself

Abstract

objectiveWe adapted the Quality Assessment of Diagnostic Accuracy Studies 2 (QUADAS-2) tool for studies of cervical cancer screening and management and used the adapted tool to evaluate the quality of studies included in a systematic review supporting the 2019 Risk-Based Management Consensus Guidelines.

methodsWe evaluated the quality of all studies included in our systematic review for postcolposcopy (n = 5) and posttreatment (n = 23) surveillance using QUADAS-2 criteria. Subsequently, we adapted signaling questions to indications of cervical cancer screening and management. An iterative process was carried out to evaluate interrater agreement between 2 study authors (M.A.C. and N.W.). Discrepant ratings were discussed, and criteria were adapted accordingly. We also evaluated the influence of study quality on risk estimates and between study variation using stratified subgroup meta-analyses.

resultsTwelve signaling questions for bias assessment that were adapted to or newly developed for cervical cancer screening and management are described here. Interrater agreement on bias assessment increased from 70% to 83% during the adaptation process. Detailed assessment of bias and applicability showed that all studies on postcolposcopy management and 90% of studies on posttreatment management had high risk of bias in at least 1 domain. Most commonly, high risk of bias was observed for the patient selection domain, indicating the heterogeneity of study designs and clinical practice in reported studies.

conclusionsThe adapted QUADAS-2 will have broad application for researchers, evidence evaluators, and journals who are interested in designing, conducting, evaluating, and publishing studies for cervical cancer screening and management.

Indexed as

ColposcopyEarly Detection of CancerFemaleHumansResearchUterine Cervical Neoplasms

Identifiers

PMID32243311
PMCPMC7141754

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.